CXCR7 is highly expressed in acute lymphoblastic leukemia and potentiates CXCR4 response to CXCL12.
Recently, a novel CXCL12-binding receptor, has been identified. This CXCL12-binding receptor commonly known as CXCR7 (CXC chemokine receptor 7), has lately, based on a novel nomenclature, has received the name ACKR3 (atypical chemokine receptor 3). In this study, we aimed to investigate the expression of CXCR7 in leukemic cells, as well as its participation in CXCL12 response. Interesting, we clearly demonstrated that CXCR7 is highly expressed in acute lymphoid leukemic cells compared with myeloid or normal hematopoietic cells and that CXCR7 contributed to T-acute lymphoid leukemic cell migration induced by CXCL12. Moreover, we showed that the cellular location of CXCR7 varied among T-lymphoid cells and this finding may be related to their migration capacity. Finally, we hypothesized that CXCR7 potentiates CXCR4 response and may contribute to the maintenance of leukemia by initiating cell recruitment to bone marrow niches that were once occupied by normal hematopoietic stem cells.
Centro de Hematologia e Hemoterapia, Universidade de Campinas, Campinas, São Paulo, Brasil.
Rita de Cássia Carvalho
RCC
Melo
Centro de Hematologia e Hemoterapia, Universidade de Campinas, Campinas, São Paulo, Brasil.
Ana Leda
AL
Longhini
Centro de Hematologia e Hemoterapia, Universidade de Campinas, Campinas, São Paulo, Brasil.
Carolina Louzão
CL
Bigarella
Centro de Hematologia e Hemoterapia, Universidade de Campinas, Campinas, São Paulo, Brasil.
Mariana Ozello
MO
Baratti
Centro de Hematologia e Hemoterapia, Universidade de Campinas, Campinas, São Paulo, Brasil.
Fabiola
F
Traina
Centro de Hematologia e Hemoterapia, Universidade de Campinas, Campinas, São Paulo, Brasil ; Departamento de Ciências Biológicas, Universidade Federal de São Paulo, Diadema, São Paulo, Brasil.
Patrícia
P
Favaro
Centro de Hematologia e Hemoterapia, Universidade de Campinas, Campinas, São Paulo, Brasil.
Paula
P
de Melo Campos
Centro de Hematologia e Hemoterapia, Universidade de Campinas, Campinas, São Paulo, Brasil.
Sara Teresinha Olalla
ST
Saad
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001596:Benzylamines; D015153:Blotting, Western; D001853:Bone Marrow / Q000378:metabolism; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects / Q000235:genetics; D054377:Chemokine CXCL12 / Q000494:pharmacology*; D000080027:Cyclams; D005260:Female; D005434:Flow Cytometry; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects; D006571:Heterocyclic Compounds / Q000494:pharmacology; D006801:Humans; D019169:Jurkat Cells; D020014:K562 Cells; D007962:Leukocytes / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D034622:RNA Interference; D054387:Receptors, CXCR / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D020298:U937 Cells; D055815:Young Adult
C501896:ACKR3 protein, human; D001596:Benzylamines; D054377:Chemokine CXCL12; D000080027:Cyclams; D006571:Heterocyclic Compounds; D054387:Receptors, CXCR; D019718:Receptors, CXCR4; C088327:plerixafor